![Martyn Breeze](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martyn Breeze
Profile
Martyn Breeze worked as a Director at Amoebics Ltd., and as a Principal at both PPL Corp.
and Celltech Group Plc.
Former positions of Martyn Breeze
Companies | Position | End |
---|---|---|
Amoebics Ltd.
![]() Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Director/Board Member | 2013-07-09 |
PPL CORPORATION | Corporate Officer/Principal | - |
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | - |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
PPL CORPORATION | Utilities |
Private companies | 2 |
---|---|
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Amoebics Ltd.
![]() Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Health Technology |
- Stock Market
- Insiders
- Martyn Breeze